AngioDynamics, Inc. (ANGO) fair value analysis
Nasdaq · Updated 2026-10-19
ANGO price how computed
Valuation status
No fair-value estimate yetANGO has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for ANGO yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $11.24
- Sector
- Healthcare
- 12-month range
- $9.70–$16.13
- Market cap
- $473M
- From 52-week high
- -30.3%
- Shares outstanding
- 42.1M
- Rank in Healthcare by quality score
- #167 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
AngioDynamics, Inc. is a medical device company that develops and manufactures products used in vascular access, oncology, and interventional radiology procedures. The company operates in the United States and internationally, serving hospitals, healthcare facilities, and patients worldwide.
ANGO currently ranks #167 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $473M
- P/E (trailing)
- n/m
- Revenue (TTM)
- $325M
- Net margin
- -10.1%
- EPS (TTM)
- $-0.24
- Gross margin
- 59.4%
- Revenue growth (3-yr avg)
- 0.8%
- Shares outstanding
- 42.1M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Expanding
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 26 · oversold
- 50-day average
- $14.93
- 200-day average
- $12.43
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-08 ▲ beat (+60.0%)
2026-05 ▲ beat (+36.4%)
2026-02 ▲ beat (+118.2%)
2025-11 ▼ miss (-52.9%)
2025-08 ▲ beat (+16.7%)
2025-05 ▲ beat (+75.0%)
2025-02 ▲ beat (+123.1%)
2024-11 ▲ beat (+63.6%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 4 buy · 0 hold · 0 sell (4 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $19.8
- Target vs last price
- +76.2%
What our data shows for ANGO
- Shares are trading in the lower third of their 12-month price range of $9.70–$16.13.
- The 14-day relative strength index sits at an oversold 26.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- ANGO's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the ANGO conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — TickrTrends' derived indicators for ANGO show a notable shift in gross-margin trend, which moved from stable to expanding this week. The Healthcare sector stock is currently positioned with an awaiting full valuation verdict. This expansion in gross-margin trend represents a positive development in the company's operational efficiency metrics.
- 2026-10-10 — TickrTrends' derived indicators for ANGO showed notable weakness this week. The quality grade declined from C to F, while the relative strength index zone moved from neutral to oversold, reflecting increased downward pressure on the Healthcare sector stock during this period.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — TickrTrends' derived indicators for ANGO showed a shift in trend momentum this week, with the 50/200-day trend state moving from uptrend to mixed. This change reflects a transition in the stock's short-term price momentum relative to its longer-term trajectory. The valuation assessment for ANGO remains pending full analysis.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is ANGO stock undervalued?
TickrTrends has no fair-value estimate for ANGO yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is ANGO's TickrTrends verdict?
ANGO is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does ANGO compare to other Healthcare stocks?
ANGO ranks #167 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is ANGO overbought or oversold?
ANGO's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
Does ANGO usually beat earnings estimates?
Over its last 8 reported quarters ANGO beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about ANGO?
Of 4 analysts covering ANGO, 4 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $19.8 (+76.2% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.